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Abstract
Large populations around the world suffer from numerous but treatable health issues,
caused by either lifestyle choices or environmental factors. Over the past decades,
point-of-care testing kits have been developed to circumvent the reliance on labora-
tories, by allowing users to perform preliminary health or environmental testing from
the privacy of their homes. However, these kits heavily rely on the precision of the
user to perform the procedures, leading to increased variability in final assessments.
To eliminate user-induced errors, we present an integrated, completely sealed, and
disposable point-of-care testing prototype that exploits the benefits of microfluidics
and 3D-printing fabrication techniques. The palm-sized modular prototype consists
of a manually operated fluid handling device that allows precise mixing, filtration,
and delivery of fluids to an on-board microfluidic assay unit for subsequent detection
of specific biochemical analytes, with a minimized risk of contamination.
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1 INTRODUCTION
Currently, the most common at-home infectious disease
tests1 and on-site water quality testing kits2 are designed to
force users to independently collect fluid samples, manually
measure and mix specified reagents, and perform assays
using the allocated components of the kits. The likelihood of
obtaining false positives and erroneous analyses is high even
if kits offer the advantage of obtaining the assessments within
a fewminutes to a few hours. Additionally, the exposed nature
of the fluid handling components increases the risk of biocon-
tamination. On the other hand, more precise assessments can
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be accomplished by shipping the pre-processed fluid samples
to a designated laboratory, with the drawbacks of increased
costs and prolonged waiting times to obtain the assessments.
To address these issues, we are developing a modular sys-
tem consisting of two components: (i) the fluid handling
device (FHD) module and (ii) an interchangeable assay mod-
ule. The FHD is designed to allow users to collect and mix
a fluid sample with preloaded reagents, filter the mixture,
sequentially deliver the processed sample to an on-board
microfluidic assay device, and collect the fluid wastes, within
a sealed system, thereby reducing user-induced variability and
contamination, while obtaining the assay results within a few
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F IGURE 1 Schematic illustrating the (A) components of the fluid handling device (FHD), (B) fabrication strategy of the microfluidic assay
module, (C) quantification of non-specific protein adsorption in the FHD. (D) Images depict the processing steps for an anti-MOMP IgG
fluorescence assay using the integrated prototype. The graph and fluorescence images depict the linear range of detectable anti-MOMP IgG
concentrations with the integrated prototype.
minutes. After the completion of the tests, the user can simply
dispose the sealed prototype as designated laboratory waste.
As a case study, we carried out biochemical assays to detect
antibodies specific to bacterial Chlamydia trachomatis infec-
tions using our integrated prototype. Specifically, buffer sam-
ples doped with C. trachomatis specific immunoglobulin G
(IgG) antibodies3 were mixed with on-board fluorescently
labeled antibodies in the FHD and assayed in poly(methyl
methacrylate) (PMMA) microfluidic assay devices, patterned
with antigenic major outer membrane proteins (MOMP) of C.
trachomatis.4 Varying concentrations (125 ng/mL - 2 µg/mL)
of anti-MOMP IgGs could be detected and reproducibly dif-
ferentiated from negative samples using our manually pow-
ered prototype within 15 min. The efficiency of this proof-
of-concept test demonstrates the capability of our integrated
prototype to enable precise, reproducible, and rapid diagnosis,
with minimized risk of contamination.
2 EXPERIMENTAL
The FHD body (Figure 1A) was fabricated using the Form2
stereolithography 3D printer (Formlabs, USA) and white V4
photocurable resin (made of methacrylic acid esters). The
custom-made components have a piston-cylinder relationship
that allows them to slide concentrically within one another,
for delivering fluid to chambers without leakage.5 For the
non-specific protein adsorption studies, three sets (n) of FHD
were soaked in N101 blocking buffer (1:5, N101:phosphate-
buffered saline (PBS)) for 15 h at 4◦C. Fluorescently labeled
IgG solutions (1.5 mL) were loaded into the reagent stor-
age units of either blocked or pristine FHD bodies (n = 3).
The concentrations of antibodies in the eluates were quanti-
fied using the NanoDropTM 2000c spectrophotometer (Ther-
moFisher Scientific, Japan), post fluid processing using the
FHD.
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The microfluidic chlamydia assay module was fabricated
by first covalently immobilizing MOMP (50 µg/mL) onto
PMMA substrates, using our developed air-plasma enhanced
bio-functionalization strategy.6 Next, double-sided adhesive
tapes were cut to form microchannels using a carbon diox-
ide laser cutter (VLS 3.50, Universal Laser Systems, USA),
and bonded to the MOMP-functionalized PMMA strips on
one side and IPA-cleaned PMMA strips on the other side to
complete the microfluidic device (Figure 1B). The bare sur-
faces of the PMMA microchannels were finally blocked with
1% weight/volume of bovine serum albumin, to prevent non-
specific adsorption of proteins, and attached to the upper por-
tion of the FHD using M3 bolts to complete the assembled
prototype.
3 RESULTS AND DISCUSSION
The FHD is a two-piece locking system (Figure 1A) that incor-
porates sample collection, sample dilution, filtration, and fluid
delivery into one easy-to-use manually operated device. The
FHD is the base module for our point-of-care testing sys-
tem, where it serves as a platform to secure different anal-
ysis/detection modules for subsequent biochemical tests. The
reagent storage cartridge is capable of housing 1- 3 mL of pri-
mary reagents, used for sample dilution and priming for the
biochemical assay. Once the sample is deposited, the lower
portions of the FHD are locked with the upper portions that
consist of secondary reagents (0.5-3 mL) employed during the
assay. Sample dilution andmixing is then performed bymanu-
ally pulling down on the ergonomic buffer cartridge tabs. This
action induces a vacuum pressure within the mixing cylin-
der and forces the primary reagents to flow into the mixing
chamber, thereby mixing and diluting the deposited sample.
The diluted sample is then subsequently passed through the
upper portion of the FHD for filtration and assay within the
on-boardmicrofluidic assaymodule, while allowing the waste
fluid to be collected in the waste unit (Figure 1A). Finally,
the secondary reagents are delivered to the microfluidic assay
module by a final compression step, completing the assay and
allowing the user to visualize the results. The photographs
illustrating the processing steps are depicted in Figure 1D.
To test if our integrated prototype can carry out effec-
tive biochemical assays efficaciously, a proof-of-concept anti-
body assay was performed to detect bacterial C. trachomatis
infections.7 PBS samples (4 mL) doped with 2 µg/mL of anti-
MOMP immunoglobulins (IgGs) served as the fluid sample
and blank PBS served as the negative control, which were pro-
cessed with six individual FHD modules, respectively (three
for each condition). The samples were loaded onto the lower
portion of the FHD and mixed with the primary reagent
buffer (2 mL) comprising fluorescently-labeled detection
antibodies, as described above. The mixed samples were fil-
tered through the upper portion of the FHD and delivered
to MOMP patterned microfluidic assay modules to detect
the presence of the anti-MOMP IgGs in the fluid sample.
The microfluidic assay module was washed by delivering
the secondary wash buffer (0.05% Tween-20 in PBS) to
remove unbound biomolecules, and imaged via fluorescence
microscopy for qualitative analysis. The inner layers of the
FHD body showed minimal non-specific protein adsorption,
with an insignificant difference between the blocked and pris-
tine units (Figure 1C). As seen in Figure 1D, the integrated
prototype enabled the detection of anti-MOMP IgGs with a
linear concentration range of 125 ng/mL - 2 µg/mL, and a
limit of detection8 of 1.05 µg/mL. The assay could be reliably
differentiated from the negative controls reproducibly in each
device, thereby demonstrating the potential of our prototype
for point-of-care testing applications.
Current research is focused on minimizing sample vol-
ume requirements by optimizing FHD design that minimizes
dead volume, and improving the sensitivity of the microflu-
idic assay modules. Additionally, the microfluidic assay mod-
ules are being engineered to test multiple biochemical ana-
lytes from a single biological sample with our integrated
device.
4 CONCLUSION
By exploiting the benefits of microfluidics and state-of-the-
art fabrication techniques using 3D printing, we developed a
completely integrated, easy-to-use, hand-held, manually pow-
ered and disposable fluid processing, and biochemical assay
device. The potential of our prototype to serve as point-of-
care testing devices was demonstrated by detecting antibodies
specific to C. trachomatis infections. In the future, we envi-
sion the inclusion of multiplexed microfluidic assay chambers
within one single device, to allow detection of multiple bio-
analytes from one single sample, thereby reducing both the
testing time (<30 min) and the cost (< US$25 for multiple
tests), for discrete at-home testing.
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